Zai Lab Limited IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Zai Lab Limited | ZLAB - NASDAQ |
$16.00-$18.00 | $18.00 | $24.25 | 8.0 million ADSs | 9/20/2017 |
| J.P. Morgan, Citigroup, Leerink Partners | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2017-08-15 Terms Added 2017-09-01 | ||||||
Zai Lab Limited Quote & Chart - Click for current quote - ZLAB
IPO Boutique aggregates information on public companies and private companies, such as "ZLAB " IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Zai Lab Limited (adapted from Zai Lab Limited prospectus):
They are an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ZLAB " IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.